文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

重症急性胰腺炎经皮穿刺引流期间行连续性肾脏替代治疗的效果:一项回顾性队列研究

[Effect of continuous renal replacement therapy during percutaneous drainage in severe acute pancreatitis patients: a retrospective cohort study].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2019-01-01
一句话结论在重症急性胰腺炎接受经皮穿刺引流的患者中,同期行连续性肾脏替代治疗安全可行,不增加出血风险,但可能延迟穿刺引流时机并延长ICU及住院时间。

该回顾性队列研究纳入2015年11月11日至2018年5月13日西安交通大学第一附属医院肝胆外科收治的75例接受经皮穿刺引流的重症急性胰腺炎患者,其中30例接受连续性肾脏替代治疗(CRRT组),45例未接受(对照组)。两组基线性别、年龄、体质指数、病史、病因、入院48小时内白细胞计数、C反应蛋白、降钙素原、液体复苏、机械通气、血管活性药物使用及腹腔内压无显著差异,但CRRT组入院48小时内急性生理与慢性健康评分Ⅱ显著高于对照组(18.3±4.5 vs. 12.8±6.2,P<0.05)。穿刺引流前两组白细胞计数、降钙素原、急性生理与慢性健康评分Ⅱ及CT严重指数无显著差异;CRRT组穿刺引流时间间隔显著长于对照组(19.4±5.4天 vs. 12.8±2.2天,P<0.05),ICU住院时间和总住院时间均显著延长(23.2±8.5天 vs. 15.3±12.1天;51.2±21.2天 vs. 31.2±14.0天,均P<0.01),而引流液性质、腹腔出血、感染、胃肠瘘、内镜下坏死组织清除、开腹坏死组织清除及穿刺引流至内镜或开腹手术时间无显著差异。Kaplan-Meier生存分析显示两组1年及3年累积生存率无显著差异(χ²₁=0.097,P₁=0.755;χ²₂=0.013,P₂=0.908)。作者认为CRRT在重症急性胰腺炎经皮穿刺引流患者中安全可行,不增加出血风险,但可能延迟穿刺引

要点

  • 在重症急性胰腺炎接受经皮穿刺引流的患者中,同期行CRRT不增加腹腔出血、感染、胃肠瘘等并发症风险。
  • CRRT组穿刺引流时间间隔显著长于对照组(19.4±5.4天 vs. 12.8±2.2天,P<0.05),提示CRRT可能延迟穿刺引流干预时机。
  • CRRT组ICU住院时间及总住院时间均显著长于对照组(23.2±8.5天 vs. 15.3±12.1天;51.2±21.2天 vs. 31.2±14.0天,均P<0.01)。
  • 两组1年及3年累积生存率无显著差异(χ²₁=0.097,P₁=0.755;χ²₂=0.013,P₂=0.908)。
  • CRRT组入院48小时内APACHEⅡ评分显著高于对照组(18.3±4.5 vs. 12.8±6.2,P<0.05),基线病情更重。

适用人群与场景

  • 2015年11月11日至2018年5月13日西安交通大学第一附属医院肝胆外科收治的接受经皮穿刺引流的重症急性胰腺炎患者。
  • 按是否接受CRRT分为CRRT组(30例)和对照组(45例)。

处置流程与药物剂量

  • CRRT组在经皮穿刺引流期间接受连续性肾脏替代治疗,具体处方(剂量、模式、疗程)原文未报告。

研究设计与关键结果

  • 回顾性队列研究,纳入75例接受经皮穿刺引流的重症急性胰腺炎患者,CRRT组30例、对照组45例。
  • 两组基线性别、年龄、体质指数、吸烟饮酒史、心血管疾病、慢性肺病、糖尿病、慢性肾功能不全、病因、入院48小时内白细胞计数、C反应蛋白、降钙素原、液体复苏、机械通气、血管活性药物及腹腔内压无显著差异;CRRT组入院48小时内APACHEⅡ评分显著高于对照组(18.3±4.5 vs. 12.8±6.2,P<0.05)。
  • 穿刺引流前两组白细胞计数、降钙素原、APACHEⅡ评分及CTSI无显著差异;两组穿刺引流位置及次数无显著差异,但CRRT组穿刺引流时间间隔显著长于对照组(19.4±5.4天 vs. 12.8±2.2天,P<0.05)。
  • 两组引流液性质、腹腔出血、感染、胃肠瘘、内镜下坏死组织清除、开腹坏死组织清除及穿刺引流至内镜或开腹手术时间无显著差异;CRRT组ICU住院时间及总住院时间均显著长于对照组(23.2±8.5天 vs. 15.3±12.1天;51.2±21.2天 vs. 31.2±14.0天,均P<0.01)。
  • Kaplan-Meier生存分析显示两组1年及3年累积生存率无显著差异(χ²₁=0.097,P₁=0.755;χ²₂=0.013,P₂=0.908)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为CRRT在重症急性胰腺炎经皮穿刺引流患者中安全可行,不增加出血风险,但可能延迟穿刺引流干预时机并延长ICU及住院时间,临床医生应予以关注。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the clinical efficacy and safety of continuous renal replacement therapy (CRRT) in patients with severe acute pancreatitis (SAP) receiving percutaneous drainage (PCD).

METHODS: Clinical data of SAP patients receiving PCD admitted to department of hepatobiliary surgery of the First Affiliated Hospital of Xi'an Jiaotong University from November 11th 2015 to May 13th 2018 were retrospectively analyzed. The patients were divided into CRRT group and control group according to whether or not receiving CRRT. Demographic data, relevant variables before and after PCD, complication and outcome were all compared.

RESULTS: A total of 75 patients were included in the study, 30 were treated with application of CRRT and 45 without CRRT. (1) There was no significant difference in gender, age, body mass index (BMI), medical history (smoking, drinking), complications (cardiovascular disease, chronic lung disease, diabetes, chronic renal insufficiency), etiology (gallstone, alcohol abuse, hyperlipidemia and others), or white blood cell count (WBC), C-reactive protein (CRP), serum procalcitonin (PCT), fluid resuscitation, mechanical ventilation, vasoactive agent or intra-abdominal pressure within 48 hours after admission between the two groups. However, acute physiology and chronic health evaluation II (APACHE II) score within 48 hours after admission of CRRT group was significantly higher than that of control group (18.3±4.5 vs. 12.8±6.2, P < 0.05). (2) There was no significant difference in WBC, PCT, APACHE II score or computed tomography severity index (CTSI) before PCD between the two groups. There was no significant difference in the position or times of PCD procedure between the two groups, but the time interval of PCD in the CRRT group was significantly longer than that in the control group (days: 19.4±5.4 vs. 12.8±2.2, P < 0.05). Meanwhile, there was no significant difference in drainage of fluid properties, incidence of abdominal bleeding, infection, gastrointestinal fistula, endoscopic removal of necrotic tissue, laparotomy for removal of necrotic tissue or the time from PCD to endoscopy or laparotomy between two groups. However, the length of intensive care unit (ICU) stay and the length of hospital stay in the CRRT group were significantly longer than those in the control group (days: 23.2±8.5 vs. 15.3±12.1, 51.2±21.2 vs. 31.2±14.0, both P < 0.01). (3) Kaplan-Meier survival analysis showed that there was no significant differences in 1-year or 3-year cumulative survival rates between the two groups (χ21 = 0.097, P1 = 0.755; χ22 = 0.013, P2 = 0.908).

CONCLUSIONS: CRRT is safe and feasible in the treatment of SAP patients receiving PCD procedure. It does not increase the risk of bleeding and may delay the time interval of PCD intervention. However, it may prolong the length of ICU stay and the length of hospital stay. It should be worthy of much attention for clinicians.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Sun B, Zhang C, Lin T, et al. [Effect of continuous renal replacement therapy during percutaneous drainage in severe acute pancreatitis patients: a retrospective cohort study]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019. PMID: 31315729. doi:10.3760/cma.j.issn.2095-4352.2019.06.011

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。